- Home
- AAL vs ROIV Comparison
AAL vs ROIV Comparison
Compare AAL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAL | ROIV |
|---|---|---|
| Founded | 1930 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AAL | ROIV |
|---|---|---|
| Price | $15.53 | $22.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | $15.34 | ★ $24.31 |
| AVG Volume (30 Days) | ★ 52.3M | 8.3M |
| Earning Date | 01-22-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.68 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $54,294,000,000.00 | $20,329,000.00 |
| Revenue This Year | $2.04 | N/A |
| Revenue Next Year | $6.60 | $741.42 |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | ★ 1.27 | N/A |
| 52 Week Low | $8.50 | $8.73 |
| 52 Week High | $19.10 | $23.47 |
Technical Indicators
Market Signals| Indicator | AAL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 56.28 |
| Support Level | $15.02 | $21.36 |
| Resistance Level | $15.44 | $22.72 |
| Average True Range (ATR) | 0.45 | 0.72 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 44.78 | 32.69 |
Price Performance
Historical ComparisonAbout AAL American Airlines Group Inc.
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of US legacy carriers.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.